French laboratory Sanofi today released positive results of a clinical trial of the main candidate vaccine against Covid-19, which he developed together with the British GlaxoSmithKline (GSK), after a failure that caused months of delay, reports APE.
The intermediate results of this phase 2 test in humans indicate that the administration of this vaccine “Caused the production of increased concentrations of neutralizing antibodies in adults of all ages at levels comparable to those seen in people who had recovered from an infection, ”the lab said in a statement today.
A phase 3 study, the last in humans before possible recombination of this vaccine based on recombinant protein, is to begin in the coming weeks, Sanofi, which will start production at the same time.
Intermediate results show antibody production in 95% to 100% of cases after a second dose in all age groups (18 to 95 years) and for all doses studied.
In those participants who were already infected with Covid-19, a single dose of the vaccine caused them to produce elevated concentrations of neutralizing antibodies, “something that underscores the growing interest in booster vaccination,” says Sanofi.
The candidate vaccine of Sanofi and GSK use the same technology as Sanofi seasonal flu vaccines. It will be combined with an adjuvant drug, a substance that acts as a vaccine booster, which is produced by GSK.
Today’s announcement is a relief for Sanofi and GSK after they were forced to resume testing last December and delay the release of the vaccine, when it showed a low immune response in older adults as a result of poor antigen formation.
It also allows the two companies to stay on the Covid-19 vaccine race.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
